Key Documents

View All Documentation

SML1772

Givinostat hydrochloride hydrate

Name: Givinostat hydrochloride hydrate
Brand: SIGMA

≥95% (HPLC), HDAC inhibitor, powder

Synonym(s):

Diethyl-[6-(4-hydroxycarbamoyl-phenyl carbamoyloxymethyl)-naphthalen-2-yl methyl]-ammonium chloride, ITF2357, N-[4-[(Hydroxyamino)carbonyl]phenyl]-carbamic acid, [6-[(diethylamino)methyl]-2-naphthalenyl]methyl ester hydrochloride

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₂₄H₂₇N₃O₄ · HCl · H₂O

CAS Number:

732302-99-7

Molecular Weight:

475.97

NACRES:

NA.77

UNSPSC Code:

12352200

MDL number:

MFCD18385007

Assay:

≥95% (HPLC)

Form:

powder

Storage condition:

desiccated

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

Product Name

Givinostat hydrochloride hydrate, ≥95% (HPLC)

Quality Segment

100

assay

≥95% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: 20 mg/mL, clear

storage temp.

−20°C

SMILES string

[H]Cl.[H]O[H].CCN(CC)CC1=CC=C(C=C(COC(NC2=CC=C(C(NO)=O)C=C2)=O)C=C3)C3=C1

InChI

1S/C24H27N3O4.ClH.H2O/c1-3-27(4-2)15-17-5-7-21-14-18(6-8-20(21)13-17)16-31-24(29)25-22-11-9-19(10-12-22)23(28)26-30;;/h5-14,30H,3-4,15-16H2,1-2H3,(H,25,29)(H,26,28);1H;1H2

InChI key

FKGKZBBDJSKCIS-UHFFFAOYSA-N

Description

Application

Givinostat hydrochloride hydrate has been used as a histone deacetylase inhibitor to test its effect on the human immunodeficiency virus reactivation in CD4⁺ T-cell model.

Biochem/physiol Actions

Givinostat (ITF2357) is a hydroxamate HDAC inhibitor that inhibits class I and class II enzymes.

Givinostat (ITF2357) is a hydroxamate HDAC inhibitor that inhibits class I and class II enzymes. Givinostat posseses a very promising activity profile in multiple myeloma and acute myelogenous leukemia in vitro and in vivo. Givinostat also has anti-inflammatory activity and inhibits the secretion of the tumor necrosis factor-alpha (TNF-α), IL-1, and IL-6. Givinostat has been in multiple Phase 2 studies for both inflammatory diseases (Duchenne Muscular Dystrophy , Juvenile arthritis, Polycythemia Vera) and blood cancers (myelomas and lymphomas).

Givinostat is known to mediate the reduction of the human immunodeficiency virus release in macrophages.

pictograms

GHS07

signalword

Warning

hcodes

H302

pcodes

P264 - P270 - P301 + P312 - P501

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c